Literature DB >> 12057111

Primary central nervous system lymphomas.

L M DeAngelis1.   

Abstract

Primary central nervous system lymphoma (PCNSL) is widely regarded as one of the primary brain tumors most amenable to treatment. Although whole brain radiotherapy was the cornerstone of therapy for decades, recent work clearly indicates that chemotherapy has become the primary focus of treatment for this disease. The initial treatment of PCNSL for all patients, including the elderly, should be chemotherapy using a high-dose methotrexate-based regimen. Although cranial irradiation has often been combined with methotrexate, the unacceptably high incidence of late neurotoxicity, particularly in older patients, has caused many to eliminate radiotherapy, especially in those older than age 60 years. Emerging data support the validity of this approach, and the development of more efficacious chemotherapeutic regimens has been the focus of recent research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12057111     DOI: 10.1007/s11864-001-0024-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  15 in total

1.  Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.

Authors:  M Reni; A J Ferreri; C Landoni; E Villa
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

2.  Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.

Authors:  M Reni; A J Ferreri; M P Garancini; E Villa
Journal:  Ann Oncol       Date:  1997-03       Impact factor: 32.976

3.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.

Authors:  D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors:  L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

5.  A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors.

Authors:  M J Glantz; B F Cole; M H Friedberg; E Lathi; H Choy; K Furie; W Akerley; L Wahlberg; A Lekos; S Louis
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.

Authors:  G M Mead; N M Bleehen; A Gregor; J Bullimore; D Shirley; R P Rampling; J Trevor; M G Glaser; P Lantos; J W Ironside; T H Moss; M Brada; J B Whaley; S P Stenning
Journal:  Cancer       Date:  2000-09-15       Impact factor: 6.860

7.  CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases.

Authors:  X Yu; Z Liu; Z Tian; S Li; H Huang; Q Zhao; Y Xu; Y Cui; X Yu
Journal:  Chin Med J (Engl)       Date:  1998-04       Impact factor: 2.628

Review 8.  Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.

Authors:  A J Ferreri; M Reni; E Villa
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

9.  Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy.

Authors:  A V Kulkarni; A Guha; A Lozano; M Bernstein
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

10.  Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.

Authors:  R J Freilich; J Y Delattre; A Monjour; L M DeAngelis
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  4 in total

1.  Absence of immunoglobulin class switch in primary lymphomas of the central nervous system.

Authors:  Manuel Montesinos-Rongen; Roland Schmitz; Cornelius Courts; Werner Stenzel; Dörte Bechtel; Gerald Niedobitek; Ingmar Blümcke; Guido Reifenberger; Andreas von Deimling; Berit Jungnickel; Otmar D Wiestler; Ralf Küppers; Martina Deckert
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 2.  Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.

Authors:  Sarah E Coupland; Heinrich Heimann; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-29       Impact factor: 3.117

Review 3.  Primary vitreoretinal lymphoma.

Authors:  Kaustubh Mulay; Ritesh Narula; Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

Review 4.  Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.

Authors:  Ramesh Venkatesh; Bharathi Bavaharan; Padmamalini Mahendradas; Naresh Kumar Yadav
Journal:  Clin Ophthalmol       Date:  2019-02-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.